No Data
No Data
Maxim Group Maintains Aytu BioPharma(AYTU.US) With Buy Rating, Maintains Target Price $8
Maxim Group analyst Naz Rahman maintains $Aytu BioPharma(AYTU.US)$ with a buy rating, and maintains the target price at $8.According to TipRanks data, the analyst has a success rate of 26.5% and a tot
It's Unlikely That The CEO Of Aytu BioPharma, Inc. (NASDAQ:AYTU) Will See A Huge Pay Rise This Year
Aytu BioPharma Announces Paydown and Refinancing of Term Loan on More Favorable Terms
Aytu BioPharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
Q3 2024 Aytu Biopharma Inc Earnings Call
Aytu BioPharma | 10-Q: Quarterly report
No Data